Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, ...
Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...
Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...
Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...
Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...
Deutsche Bank upgraded Sanofi (SNY) to Hold from Sell with a price target of EUR 100, up from EUR 85, following the company’s “solid” Q4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback